Bivision
Latest round
- Series B
Last raised
- May 2026
Total raised
- $101M
Investors
- 17
About Bivision
Based in Shanghai, China, and founded in 2021, Bivision is a biopharmaceutical developer focused on developing next-generation targeted radionuclide therapies that are image-guided and integrate diagnosis and treatment. The company's co-founder, Haihua Yu, is a PhD in Medicinal Chemistry, Fudan University. In December 2023, its drug, JH02, completed Phase I clinical trials. Bivision has three major technology platforms which are targeted ligand screening, radioactive drug conjugation, and drug clinical transformation. The company's technology platforms can be used for ligand screening, modulation of coupling factors (J-Linker) and clinical transformation. Its product pipeline includes JH002, JH003, JH004, N001 and N002. The drugs can be used to treat cancer. The company generates revenue by developing drugs that can be used to treat cancer. The company will use the funds for the clinical advancement of JH02, IND application and clinical development of JH04, as well as subsequent preclinical studies and IIT studies of multiple global innovative pipelines. The company will also continue to promote its global layout, including the launch of overseas clinical trials and cooperative development of overseas rights and interests of projects.
Who invested in Bivision
17 investors across 5 rounds
See all investors in Bivision
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Bivision
Who invested in Bivision?
Bivision has 17 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Bivision raised?
Bivision has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Bivision last raise money?
Bivision's most recent round on record is a Series B, in May 2026.
What does Bivision do?
Based in Shanghai, China, and founded in 2021, Bivision is a biopharmaceutical developer focused on developing next-generation targeted radionuclide therapies that are image-guided and integrate diagnosis and treatment.
Where is Bivision headquartered?
Bivision is headquartered in Shanghai, China.
Which VCs invest in companies like Bivision?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Bivision's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Bivision? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.